confirm amount to pledge

You must pledge an amount that will buy a whole number of shares
(the share price is £1.25)
  • Target

    £800,000

  • Type

    Equity

  • Close Date

    Dec 1 2018

  • Status

    Closed

RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.

Tharos

NATURE POWERED BY SCIENCE Advancing Horse Health and Performance through Science-driven Innovation

Tharos logo
£

A pledge is not a commitment. You will be asked to confirm in the next section.

Track
Contact

Locked

This section is currently locked.
Please Sign Up or Log In to unlock.
Companies
House

Locked

This section is currently locked.
Please Sign Up or Log In to unlock.
Twitter

Twitter

Overview

THAROS™ believe in nature powered by science. THAROS™ promote equine health and wellbeing through world-class innovation. Their microbiome research is leading to the development of a number of future products to assist animal health through restored gut function. THAROS™ provides the support for professional riders and horse lovers who seek to release the highest levels of performance and potential from their horses.

  • The state of the gut is of critical importance to humans and animals alike. It has a direct effect on health and performance. The impact of the microbiome – including bacteria, fungi and viruses – in the gut is now coming under scrutiny. It is these microbiomes in animals that form the scientific focus of THAROS™.

  • 2018 will see the market launch of the first THAROS™. product, EquiNectar® horse feed – the culmination of years of research and development. EquiNectar® is the commercialised form of enzyme rich malt extract (ERME), which has been shown to improve the health and performance of racehorses suffering from common digestive problems. 

  • Contributing to a four-fold increase in prize money during in-feed trials at one leading race yard, EquiNectar® has been described as “a game-changer” by a leading figure in the sector. The original product is being followed up with the development of alternative formats, and with further potential applications in the equine sector and other animals.

Equinectar 129
Deal Manager avatar

Deal Manager
Agne Pakalniskyte

  • Sector: Healthcare
  • Region: UK: South-West
  • Stage: Early Stage - some revenues, pre-profit
  • Eligible Tax: EIS
  • Board Requirement: Board In Place
  • Pre Money Valuation: £2,799,986
  • Share Price: £1.25
  • Originator: Envestors
This section is currently locked.
Please Sign Up or Log In to unlock.

Lead Investor

661538510 780x439

Anglo Scientific

The investors and entrepreneurs of Anglo Scientific, strive to build technology led companies underpinned by groundbreaking science that we have either invented ourselves or sourced from gifted third parties. These technologies have the potential to deliver disruptive products to address identified large market opportunities in their areas of expertise: healthcare, security & communications.

Team

This section is currently locked.
Please Sign Up or Log In to unlock.

Market

This section is currently locked.
Please Sign Up or Log In to unlock.

Investment

This section is currently locked.
Please Sign Up or Log In to unlock.

Discussions

This section is currently locked.
Please Sign Up or Log In to unlock.

Documents

1 documents are currently locked.
To unlock the Public Data Room you will need to Sign Up or Login

Originator


Originator: Envestors

Investment Focus: Equity and Debt

About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.

Contact Name: Oliver Woolley

  • Registered Investors
    Over 1000
  • Investment through platform
    Over £100m